Immunotherapy of melanoma
Open Access
- 1 January 2018
- journal article
- Published by Termedia Sp. z.o.o. in Contemporary Oncology
- Vol. 2018 (1) , 61-67
Abstract
The immunotherapy is currently changing the landscape of oncology. Nowadays the standard of care in metastatic or unresectable melanoma patients include immunomodulating modalities such as anti-PD-1 drugs (nivolumab, pembrolizumab) and anti-CTLA-4 antibody ipilimumab. The improvements of...Keywords
This publication has 39 references indexed in Scilit:
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeScience, 2017
- IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and ToleranceTrends in Immunology, 2016
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic CorrelatesJournal of Clinical Oncology, 2010
- Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1New England Journal of Medicine, 2008
- A Phase I Study of OncoVEXGM-CSF, a Second-Generation Oncolytic Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating FactorClinical Cancer Research, 2006
- A critical role for the programmed death ligand 1 in fetomaternal toleranceJournal of Experimental Medicine, 2005
- Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenaseNature Medicine, 2003
- Prevention of Allogeneic Fetal Rejection by Tryptophan CatabolismScience, 1998
- CD4/major histocompatibility complex class II interaction analyzed with CD4‐ and lymphocyte activation gene‐3 (LAG‐3)‐Ig fusion proteinsEuropean Journal of Immunology, 1995
- [Melanoma (Hutchinson's lentigo maligna) having spontaneous regression. A case of immunologic importance].1980